Reported safety narratives, with historical warnings and uncertain findings separated. Read the record and supporting citations before drawing conclusions.
ChEMBL withdrawn_flag true; not an FDA-approved drug product
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.Systemic heparin carries HIT risk; nebulised route not an approved formulation
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.ChEMBL withdrawn flag set (formulation-specific); no major safety withdrawal for the flavonoid itself
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.ChEMBL withdrawn_flag set; bleeding risk (antiplatelet interaction). No rigorous FDA drug approval.
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.Esketamine (Spravato) carries FDA boxed warning: sedation, dissociation, abuse/misuse potential
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.5 FDA warnings; CKD +20-50%; fractures +30%; $590M settlements
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.No primary citation attached yet.
US FDA repeatedly declined approval (cardiovascular concerns incl. increased MI after cardiac bypass at high doses)
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.FDA Nonprescription Drugs Advisory Committee (Sept 2023) concluded oral phenylephrine is ineffective as a decongestant; FDA proposed removing oral OTC phenylephrine (2024)
The note concerns a different formulation, related agent, efficacy, or an insufficiently specified source. Excluded from definitive safety and setback totals pending review.